Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE-AA-PEDS: Baricitinib in Pediatric Alopecia Areata
NCT05723198Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 12
01
Overview
A Phase 3 trial of baricitinib in alopecia areata, sponsored by Eli Lilly and Company. Started Feb 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05723198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723198.